Comparing Treatments for Advanced Melanoma
Author Information
Author(s): Middleton M R, Lorigan P, Owen J, Ashcroft L, Lee S M, Harper P, Thatcher N
Primary Institution: CRC Department of Medical Oncology, Christie Hospital NHS Trust
Hypothesis
Is there a difference in response rate and survival between two treatment regimens for advanced melanoma?
Conclusion
The study found no significant difference in response rates or overall survival between the two treatment regimens for advanced melanoma.
Supporting Evidence
- One hundred and five patients were randomized to receive either DTIC/IFN or DBCT.
- The response rate was 17.3% with DTIC/IFN and 26.4% with DBCT.
- Median overall survival was similar at 199 days for DTIC/IFN and 202 days for DBCT.
- One-year survival rate was 30.6% for standard treatment and 22.6% for combination therapy.
- DBCT was associated with significantly greater haematological toxicity.
Takeaway
Doctors wanted to see if one treatment for melanoma was better than another, but they found out that both worked about the same.
Methodology
Patients were randomized to receive either standard therapy or combination chemotherapy and were monitored for response rates and survival.
Limitations
The study may not have had enough power to detect small differences in survival rates.
Participant Demographics
Patients with advanced melanoma, 105 randomized with 100 eligible.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website